SecBot SecBot
6-K ·Filed Mar 26, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001654954-26-002780
Notable filing: 6-K
Actionable Insight • Neutral

Monitor future buyback activity and total program size; assess impact on EPS and capital allocation strategy. Consider potential signal of management confidence, but note this is a routine program execution.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$53.94
T+0 close · Mar 26, 2026 · via day close
Latest settled
−4.17%
T+60 · $51.69
Vs SPY
−18.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $53.94entry
  2. T+1 · 8mo ago −0.19%α +1.49% · $53.84
  3. T+5 · 8mo ago +5.10%α +3.46% · $56.69
  4. T+20 · 7mo ago +0.93%α −9.74% · $54.44
  5. T+60 · 5mo ago −4.17%α −18.12% · $51.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK plc announced the purchase of 345,000 of its ordinary shares on 25 March 2026 at a volume-weighted average price of 2,033.20 GBp per share, as part of its ongoing buyback program. Since 17 February 2026, the company has bought back 14,856,521 shares. The shares were acquired through BNP Paribas SA and will be held as treasury shares.

Key Facts

  • GSK purchased 345,000 ordinary shares on 25 March 2026
  • Volume-weighted average price paid: 2,033.20 GBp per share
  • Shares were acquired via BNP Paribas SA as part of a non-discretionary buyback program
  • Since 17 February 2026, GSK has bought back 14,856,521 shares
  • Purchased shares will be held as treasury shares

Financial Impact

Total cost of 345,000 shares at 2,033.20 GBp is approximately £7.01 million (based on GBP/USD exchange rate of 1.28, ~$9.0 million)

shares outstandingcash flow

Risk Factors

  • Buybacks reduce cash reserves and may signal limited growth investment opportunities
  • If buybacks continue at elevated pace, could constrain future R&D or M&A capacity

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-002780
Document: 0001654954-26-002780-index-headers.html0001654954-26-002780
Document: 0001654954-26-002780-index.html0001654954-26-002780
Document: 0001654954-26-002780.txt0001654954-26-002780

US Market Status

Market Closed · Opens Wed (10h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026